日韩亚洲国产综合高清_国产精品综合色区,日韩高清在线亚洲专区不卡免费看

                        關于我們    —

                    About Us

                    粵港澳干細胞生物科技有限公司  GHM Stem Cell Biotechnology Co., Ltd

                    圖片展示

                    公司概況

                           東莞粵港澳干細胞生物科技有限公司,注冊資金1億元,專注于細胞儲存、生物技術研發、以及細胞相關臨床前研究。公司立足粵港澳大灣區,旗下已成立多家子公司與東莞市恩聯干細胞生物科技研究院,并于2019年10月24日正式簽約成為國家干細胞轉化資源庫的共建單位,致力帶動生命科學與衛生醫療產業的健康發展。

                           公司主要股東為廣東名店集團、銀帝集團以及杰出海歸科學家。廣東名店集團扎根東莞20多年,主營業務范圍涉及生命科學、高新科技、大型房地產開發、金融投資等領域,董事長陳路為東莞十五屆人大常委、東莞工商聯副主席、廣東省浙江商會執行會長、東莞浙江商會會長。銀帝集團,企業注冊資金39億元。集團總部位于北京CBD核心區,董事局主席朱奕龍為中國僑聯副主席、全國政協委員,同時擔任粵港澳大灣區產融投資有限公司(注冊資本400億元)董事局主席兼總裁 。聯合創始人李治寰博士,清華大學學士、研究生,美國羅切斯特大學博士,耶魯大學、哈佛大學博士后,2014年獲美國遺傳學會Larry Sandler獎第二名,2017年入選深圳市海外高層次人才“孔雀計劃”,具有國內外頂尖學術背景和資本市場經驗。

                           粵港澳干細胞生物科技先后與中國科學院深圳先進技術研究院、同濟大學生命科學與技術學院、香港大學李嘉誠醫學院、上海市東方醫院、以及廣州醫科大學附屬第一醫院在共建聯合實驗室、共同研發項目、引進國內外高新技術人才等領域進行深度合作。

                           東莞市恩聯干細胞生物科技研究院,由東莞粵港澳干細胞生物科技有限公司與中國科學院廣州生物醫藥與健康研究院于2018年8月聯合建設,主管單位為東莞市科技局。目前已嚴格按照國家GMP標準和美國AABB標準建成一期4000平方米的實驗室,配備世界一流的儀器設備,包括德國蔡司公司生產的激光共聚焦顯微鏡、美國GT醫療公司生產的BioArchive低溫存儲罐、默克公司生產的Flowsight流式細胞儀、美國Thermo公司生產的程序降溫儀、邁瑞公司生產的血細胞分析儀等等。

                           恩聯研究院積極引進海內外頂尖專家與人才,研發團隊陣容強大,包括:譚蔚泓(中國科學院院士)、ANTONIO VIDAL-PUIG(英國醫學科學院院士、劍橋大學教授)、何建行(廣東省心血管病研究所博士)、高紹榮(中國科學院動物研究所博士)、李治寰(美國羅切斯特大學博士、哈佛大學、耶魯大學博士后)、阮建波(東莞市名醫、特色人才)、康九紅(國家杰出青年、長江學者)、康鐵邦(教育部“長江學者”特聘教授)、夏建川(哈佛大學助理研究員)、朱麟勇(國家杰出青年、“東方學者”特聘教授)、萬曉春(加拿大蒙特利爾大學博士)、暢君雷(美國哈佛醫學院博士)、林同香(美國加州大學圣地亞哥分校博士后)、賈文文(西北農林科技大學和美國賓夕法尼亞大學聯合培養博士)、樓陸軍(南部戰區空軍醫院專家組成員)、陳志凌(蘇黎世聯邦理工學院、歐洲核子研究中心博士)、劉星吟(美國羅切斯特大學和愛因斯坦醫學院博士后)、ROBERT KONRAD NAUMANN(德國柏林洪堡大學博士、德國法蘭克福馬克斯普朗克腦研究所博士后)等。

                           目前,恩聯研究院已申請了多項生物技術發明專利,并獲得廣州市微生物研究所的GMP實驗室清潔度與東莞市食品藥品檢驗所清潔度的權威認證,同時通過了ISO9001、ISO14001、OHSAS18001質量體系認證,在細胞標準化制備、安全存儲以及技術支持服務上已達到國際標準。恩聯研究院已被推舉為廣東省細胞生物學學會副理事長單位,并被吸納為中國生物醫藥技術協會會員。

                           2019年8月,東莞市衛生健康局明確支持恩聯研究院實施3年戰略目標“2+5+2計劃”,即恩聯干細胞研究院在未來三年內:將至少聯合東莞2家醫院獲得干細胞臨床研究備案機構;聯合東莞醫院在國家衛健委備案5個細胞相關項目;聯合東莞的醫院提交2個細胞新藥的臨床批件申請。該計劃的實施對促進干細胞與再生醫學技術創新、成果轉化和產業發展,助推東莞開展細胞治療具有重要意義。目前,研究院與國內多家三甲醫院及醫療機構合作共建再生醫學生物資源庫,如:上海市東方醫院、廣州醫科大學附屬第一醫院、東莞市人民醫院等19家公立醫院,為實現“健康中國夢”持續貢獻力量。


                    公司和研究院經營與研究范圍包括:

                    公司和研究院經營與研究范圍包括:

                    1. 細胞儲存:臍帶、脂肪、胎盤、牙髓間充質干細胞和免疫細胞的儲存業務;

                    2. 細胞技術服務:臨床級人源細胞技術科研服務;

                    3. 生物技術研發:新型干細胞及免疫細胞制備制劑技術研發、臨床級細胞制備存儲新技術和相關試劑的研發;

                    4. 細胞相關臨床前研究:細胞分子機理研究、細胞療法、細胞創新藥物研發、細胞抗衰老研究等。

                         GHM Stem Cell Biotechnology Co., Ltd. (GHMSCB), founded with registered capital of 100 million RMB, focuses on cell storage, biotechnology research and development, and cell related preclinical studies. GHM has several subsidiaries and Dongguan Enlife Stem Cell Biotechnology Institute (Enlife Institute). On 24 Oct 2019, GHM officially became the co-construction partner of the National Stem Cell Transformation Resource Bank, to promote the development of life sciences and healthcare industry.

                    The main shareholders of GHMSCB are Guang Dong Mingdian Group, Yindi Group and distinguished scientists. Guang Dong Mingdian Group has been operated in Dongguan City for more than 20 years, and its main business covers biotechnology, large-scale real estate projects, financial investment, etc. Chairman of the group, Lu Chen is the Vice Chairman of Industry and Commerce Federation of Dongguan City, Executive Chairman of Zhejiang Chamber of Commerce of Guangdong Province, and Chairman of Zhejiang Chamber of Commerce of Dongguan. Yindi Group, with registered capital of 3.9 billion RMB, is headquartered in the core of Beijing CBD. Chairman of the Board of Directors Mr. YiLong Zhu serves as Vice-Chairman of All-China Federation of Returned Overseas Chinese and member of the CPPCC National Committee. He is also Chairman and President of the Board of Directors of Guangdong-Hong Kong-Macao Greater Bay Area Investment Co., Ltd. (registered capital of 40 billion RMB). Co-founder Dr. Zhihuan Li received his B.S. from Tsinghua University and Ph.D. from the University of Rochester, and continued his Post-doctoral training in Yale University and Harvard University. He won the second place of Larry Sandler Memorial Award of the American Genetic Society in 2014. In 2017, he was selected as Shenzhen Peacock Overseas High-Caliber Personnel. Mr. Li has premium academic background and capital market experience at home and abroad.

                         GHMSCB has carried out in-depth cooperation with many prestigious research institutes in China, including Shenzhen Institute of Advanced Technology CAS, Tongji University, Li Ka Shing Faculty of Medicine HKU, Shanghai East Hospital, and The First Affiliated Hospital of Guangzhou Medical University, in the field of joint laboratory construction, joint research projects and introduction of domestic and foreign high-tech talents.

                         Enlife Institute was jointly founded by GHMSCB and Guangzhou Institute of Biomedicine and Health CAS in Aug 2018. It is supervised by Dongguan Science and Technology Bureau. At present, a phase I 4000 square meter laboratory has been built in strict accordance with national GMP standards and American AABB standards. The laboratory is equipped with world-class instruments and equipment, including laser confocal microscope produced by Zeiss (Germany), cryogenic storage tank BioArchive produced by GT (USA), FlowSight Imaging Flow Cytometer produced by Merck Millipore (Germany),Scientific Forma CryoMed Controlled produced by Thermo (USA), Automatic Blood Cell Analyzer produced by Mindray (China), etc.

                         Enlife Institute has endeavored to bring in top experts from home and abroad. Scientists team includes: WeiHong Tan (Academician of the Chinese Academy of Sciences), ANTONIO VIDAL-PUIG (Academician of the British Academy of Medical Sciences, Professor of Cambridge University), JianXing He (Ph.D., Guangdong Cardiovascular Institute), ShaoRong Gao (Ph.D., Institute of Zoology CAS), ZhiHuan Li (Ph.D., University of Rochester, USA. Post-doctoral, Yale University & Harvard University, USA), JianBo Ruan (Famous Doctor in Dongguan, Dongguan Talents with Special Characteristics), JiuHong Kang (Winner of National Science Fund for Distinguished Young Scholars and Changjiang Scholars), Tiebang Kang (Distinguished Professor, Yangtze River Scholar of the Ministry of Education), JianChuan Xia (Research Associate of Harvard University), LinYong Zhu (Winner of National Science Fund for Distinguished Young Scholars and Oriental Scholars), XiaoChun Wan (Ph.D., University of Montreal, Canada), JunLei Chang (Ph.D., Harvard Medical School, USA), TongXiang Lin (Post-doctoral, University of California, San Diego), WenWen Jia (Ph.D., Northwest A&F University and University of Pennsylvania), LuJun Lou (Member of the Expert Group of the Southern Theater Air Force Hospital), ZhiLing Chen (Ph.D., Zurich Federal College of Science, Swiss; Ph.D., the European Centre for Nuclear Research), XingYin Liu (Post-doctoral, University of Rochester, USA & Albert Einstein College of Medicine),ROBERT KONRAD NAUMANN (Ph.D., Humboldt-University, Berlin, Germany; Post-doctoral, Max Planck Institute for Brain Research, Frankfurt, Germany), etc.

                         At present, Enlife Institute has applied for a number of biotechnology invention patents, and obtained the authoritative cleanliness certification of GMP Laboratory of Guangzhou Institute of Microbiology and Dongguan Institute for Food and Drug Inspection. Meanwhile, it has passed ISO9001, ISO14001 and OHSAS18001 quality system certification. It means Enlife Institute has reached international standards in cell standardized preparation, safe storage and technical support. It has also been elected as deputy director unit of Guangdong Society for Cell Biology and admitted as a member of China Medicinal Biotech Association.

                         In Aug 2019, Dongguan Municipal Health Bureau explicitly supported Enlife Institute to implement a 3-year strategic goal “2+5+2 Plan”, which means within the next 3 years, Enlife Institute will assist least 2 Dongguan hospitals to become registered stem cell clinical research institutions; it will allied with Dongguan hospitals to record 5 cell related projects with the National Health Commission; and it will cooperate with Dongguan hospitals to submit 2 clinical approval applications of new cellular drugs. The implementation of the plan is of great significance to promote the technological innovation, achievement transformation and industrial development of stem cells and regenerative medicine, and to promote the development of cell therapy in Dongguan City. At present, Enlife Institute has allied with a number of 3A hospitals and medical institutions in China to build a biological resource bank of regenerative medicine, striving to the realize the “Healthy China” dream. Alliances include 16 public hospitals such as: Shanghai East Hospital, the First Affiliated Hospital of Guangzhou Medical University, Dongguan People's Hospital, etc.


                    圖片展示

                    企業文化

                    Company Culture

                    愿景

                    VISION

                    成為粵港澳大健康產業的創新驅動者

                    核心價值觀

                    CORE VALUES

                    感恩、嚴謹、責任、創新、共享、服務

                    使命

                    MISSION

                    讓人類更健康,更長壽

                    行為準則

                    PRINCIPLES OF CONDUCT

                    誠信、嚴謹、實事求是是使我們的行為準則

                    企業精神

                    Entrepreneurship

                    愛祖國、愛人民、愛事業和愛生活是我們凝聚力的源泉;責任意識、創新精神、敬業精神與團結合作精神是我們企業文化的精髓。愉悅爭取,開心接受。

                    公司和研究院經營與研究范圍包括

                    公司和研究院經營與研究范圍包括

                    Scope Of Business And Research Of the Company And The ResearchInstitute Includes

                    圖片展示

                    細胞儲存

                    臍帶干細胞、脂肪干細胞、胎盤干細胞、牙髓干細胞和免疫細胞的儲存



                    圖片展示

                    生物技術研發

                    細胞制備技術、細胞存儲技術和相關試劑的研發



                    圖片展示

                    細胞相關臨床前研究

                    干細胞相關機理研究、細胞療法、細胞藥物研發、干細胞抗衰老研究等



                    圖片展示

                    網站留言

                    官網“客戶中心”——“聯系我們”留言您的聯系方式和需求,專屬客服收到資料后將盡快與您聯系。 

                    電話咨詢

                    致電服務熱線0769-28828333,將有專屬客服為您服務。

                    公眾號咨詢

                    搜索“粵港澳干細胞”公眾號關注留言您的聯系方式等信息,我們盡快與您聯系。

                    圖片展示

                    網站留言

                    官網“客戶中心”——“聯系我們”留言您的聯系方式和需求,專屬客服收到資料后將盡快與您聯系。 

                    電話咨詢

                    致電服務熱線0769-28828333,將有專屬客服為您服務。

                    公眾號咨詢

                    搜索“粵港澳干細胞”公眾號關注留言您的聯系方式等信息,我們將第一時間與您聯系。

                    圖片展示

                     Copyright ? 粵港澳干細胞生物科技有限公司All Rights Reserved. 粵ICP備19082248號-1     網站地圖

                    日韩亚洲国产综合高清_国产精品综合色区,日韩高清在线亚洲专区不卡免费看